CA2069746A1 - Facteurs de croissance heterogenes - Google Patents

Facteurs de croissance heterogenes

Info

Publication number
CA2069746A1
CA2069746A1 CA002069746A CA2069746A CA2069746A1 CA 2069746 A1 CA2069746 A1 CA 2069746A1 CA 002069746 A CA002069746 A CA 002069746A CA 2069746 A CA2069746 A CA 2069746A CA 2069746 A1 CA2069746 A1 CA 2069746A1
Authority
CA
Canada
Prior art keywords
leu
ala
ser
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002069746A
Other languages
English (en)
Inventor
Jonathan I. Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2069746A1 publication Critical patent/CA2069746A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002069746A 1990-09-28 1991-09-26 Facteurs de croissance heterogenes Abandoned CA2069746A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58995890A 1990-09-28 1990-09-28
US589,958 1990-09-28

Publications (1)

Publication Number Publication Date
CA2069746A1 true CA2069746A1 (fr) 1992-03-29

Family

ID=24360286

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002069746A Abandoned CA2069746A1 (fr) 1990-09-28 1991-09-26 Facteurs de croissance heterogenes

Country Status (8)

Country Link
EP (1) EP0503050A4 (fr)
JP (1) JPH05502463A (fr)
AU (2) AU8735991A (fr)
CA (1) CA2069746A1 (fr)
IE (1) IE913426A1 (fr)
PT (1) PT99107A (fr)
WO (1) WO1992006116A1 (fr)
ZA (1) ZA917766B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
JP3149182B2 (ja) * 1990-08-29 2001-03-26 ジェネティックス・インスティテュート・インコーポレイテッド 多領域造血刺激因子類
US5604116A (en) * 1992-11-24 1997-02-18 G. D. Searle & Co. Interleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methods
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1995028427A1 (fr) * 1994-04-15 1995-10-26 Imclone Systems Incorporated Lymphokine chimere composee de l'interleukine 3 et d'une muteine de l'interleukine 6
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
IT1271688B (it) * 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
CA2194070A1 (fr) * 1995-04-26 1996-10-31 Haruhiko Yokoi Nouveaux polypeptides
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
JP3764487B2 (ja) * 1996-09-20 2006-04-05 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド エリスロポエチンの生物活性のインビトロでの測定方法
CN1234073A (zh) * 1996-10-25 1999-11-03 G·D·瑟尔公司 环状变更的促红细胞生成素受体激动剂
CA2268742A1 (fr) * 1996-10-25 1998-04-30 G.D. Searle & Co. Agonistes recepteurs hematopoietiques chimeriques multifonctionnels
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
DK0902085T3 (da) * 1997-09-01 2004-04-05 Aventis Pharma Gmbh Rekombinant human erythropoietin med fordelagtig glycosyleringsprofil
WO1999041382A2 (fr) * 1998-02-17 1999-08-19 Hyseq, Inc. Nouvelle interleukine 3 et ses utilisations
BR9917606A (pt) * 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
WO2006055260A2 (fr) 2004-11-05 2006-05-26 Northwestern University Utilisation de scf et de scf dans le traitement de l'ischemie cerebrale et des troubles neurologiques
KR101857825B1 (ko) 2010-03-04 2018-05-14 피페넥스 인크. 변성 없이 가용성 재조합 인터페론 단백질을 제조하는 방법
WO2011123570A2 (fr) 2010-04-01 2011-10-06 Pfenex Inc. Procédés pour la production de g-csf dans une cellule hôte de pseudomonas
TWI502016B (zh) 2012-07-31 2015-10-01 Asahi Kasei E Materials Corp Epoxy resin compositions, epoxy resins and hardened products
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203672B (it) * 1982-05-12 1989-02-15 Harvard College Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
US4935352A (en) * 1985-10-21 1990-06-19 Takeda Chemical Industries, Ltd. Expression vector for animal cell line and use thereof
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE3751664T2 (de) * 1986-08-01 1996-06-05 Commw Scient Ind Res Org Rekombinanter impfstoff
AU3864089A (en) * 1988-07-20 1990-02-19 Immunex Corporation Nonglycosylated human interleukin-3 compositions
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JPH04501808A (ja) * 1989-07-06 1992-04-02 セラジェン・インコーポレーテッド ハイブリッド分子
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE69007975T2 (de) * 1989-08-22 1994-07-21 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
JP3149182B2 (ja) * 1990-08-29 2001-03-26 ジェネティックス・インスティテュート・インコーポレイテッド 多領域造血刺激因子類

Also Published As

Publication number Publication date
JPH05502463A (ja) 1993-04-28
WO1992006116A1 (fr) 1992-04-16
ZA917766B (en) 1993-03-29
EP0503050A4 (en) 1994-07-06
AU8735991A (en) 1992-04-28
IE913426A1 (en) 1992-04-08
EP0503050A1 (fr) 1992-09-16
AU1157695A (en) 1995-04-13
PT99107A (pt) 1992-08-31

Similar Documents

Publication Publication Date Title
CA2069746A1 (fr) Facteurs de croissance heterogenes
EP0489116B1 (fr) Proteines de fusion comprenant gm-csf et il-3
US5073627A (en) Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
JP2957974B2 (ja) エリスロポエチン活性を有するタンパク質の製造方法
Sherr et al. Colony-stimulating factor 1 (macrophage colony-stimulating-factor)
JPH04506342A (ja) 非グリコシル化ヒトインターロイキン―３類似蛋白質
US5376367A (en) Fusion proteins comprising MGF and IL-3
JPH11500308A (ja) 新規ｃ−ＭＰＬリガンド
EP0342206A1 (fr) Proteines humaines il-3
JPH05268971A (ja) インターロイキン−７
WO1995033057A1 (fr) Molecule hybride de formule gm-csf-l-epo ou epo-l-gm-csf utilisee dans la stimulation hematopoietique
JPS63301798A (ja) コロニー刺激因子誘導体
JPH1080286A (ja) ヒトｉｌ−３を生産する方法及びヒトｉｌ−３活性を有するタンパク質
KR19990064068A (ko) 다기능성 조혈 수용체 아고니스트
CA2182474A1 (fr) Administration conjointe de polypeptides mutants d'interleukine-3 et de facteurs stimulant les colonies pour produire des cellules hematopoietiques multilignee
JP3287869B2 (ja) ヒト神経成長因子２の製造法
AU751498B2 (en) flt3 ligand chimeric proteins
EP0652901A1 (fr) Muteines d'interleukine-6 a terminaison carboxy
CA1341160C (fr) Facteur stimulant les colonies de granulocytes et de macrophages de bovin
JP3002104B2 (ja) 顆粒球コロニー刺激因子受容体のリガンド結合領域蛋白質ｂｃをコードしているｄｎａ

Legal Events

Date Code Title Description
FZDE Dead